Theacrine

# Research Output: Theacrine

## Chemical Identity

**Confirmed via PubChem CID 75324 [Ref 1] and chemical supplier cross-references [Ref 27]:**

| Property | Value |
|---|---|
| Common name | Theacrine |
| Systematic / IUPAC name | 1,3,7,9-tetramethylpurine-2,6,8-trione |
| Alternative systematic | 1,3,7,9-tetramethyluric acid (widely used in literature) |
| CAS number | 2309-49-1 |
| PubChem CID | 75324 |
| Molecular formula | C₉H₁₂N₄O₃ |
| Molecular weight | 224.22 g/mol |
| InChIKey | QGDOQULISIQFHQ-UHFFFAOYSA-N |
| SMILES | O=C1C2=C(N(C)C(N2C)=O)N(C)C(N1C)=O |
| Chemical class | Methylurate; purine alkaloid |

**Notes on seed data:**
- Formula, MW, IUPAC name, InChIKey, and PubChem CID were all absent in the brief's seed data. These are now confirmed.
- The SMILES field was empty in the brief; it is now confirmed from PubChem [Ref 1] and chemical supplier data [Ref 27].
- The brief's "systematic name" field matched the IUPAC name correctly.

**Natural sources:** Theacrine is found in meaningful concentrations in the leaves of *Camellia assamica* var. *kucha* (Kucha tea, ~2.8% dry weight in young leaves [Ref 16]), in the fruit of *Theobroma grandiflorum* (Cupuaçu), and in minor amounts in certain *Coffea* species [Ref 5]. It is a structural analog of caffeine, distinguished by a methylurate rather than methylxanthine scaffold — differing by C8 oxidation and N9 methylation relative to caffeine [Ref 24].

---

## Pharmacology

### Primary Mechanisms

**Adenosine receptor antagonism:** Feduccia et al. (2012 [Ref 2]) demonstrated in Long Evans rats that theacrine acts as an adenosine A₁ and A₂A receptor antagonist. Pre-treatment with theacrine significantly attenuated motor depression induced by co-administration of the A₁ agonist CPA and A₂A agonist CGS-21680. This mechanism is directly analogous to caffeine's primary mechanism, though theacrine's selectivity profile has not been characterized with formal Ki/EC50 binding assay data in the published literature.

**Dopaminergic system involvement:** The same study [Ref 2] showed that theacrine-stimulated locomotion was significantly reduced by both D₁ receptor antagonist SCH23390 and D₂ receptor antagonist eticlopride, implicating the dopaminergic system in its psychostimulant effects. Bilateral infusion into the nucleus accumbens (10–20 µg) produced dose-dependent locomotor enhancement, identifying the NAc as a key site of action [Ref 2].

**No formal Ki or EC50 data** for theacrine at adenosine receptors (A₁, A₂A) or dopamine receptors (D₁, D₂) have been reported in the published literature as of 2026. This is a notable gap.

**PDE4/cAMP/CREB/BDNF pathway (antidepressant mechanism):** Ouyang et al. (2021 [Ref 13]) demonstrated in stressed mice that theacrine's antidepressant effects operate through the PDE4/cAMP/CREB/BDNF/TrkB pathway, promoting adult hippocampal neurogenesis and counteracting chronic stress-induced 5-HT dysregulation. This mechanism is distinct from its adenosine/dopamine stimulant actions.

**SIRT3 activation (neuroprotective):** Duan et al. (2020 [Ref 12]) showed theacrine protects dopaminergic neurons in Parkinson's disease models through SIRT3 activation. The SIRT3/FOXO3a/Parkin pathway is also implicated in its anti-inflammatory effects in psoriasis [Ref 20]. Separately, in vitro data in C2C12 muscle cells showed a theacrine-containing supplement increased SIRT1 mRNA, global sirtuin activity, and NAD⁺ levels ~2-fold [Ref 35].

**Nrf2/ARE pathway (antioxidant):** Zhang et al. (2026 [Ref 25]) demonstrated in MCAO rat stroke models and HUVECs that theacrine activates the Nrf2 pathway and inhibits Rac1, reducing oxidative stress, apoptosis, and vascular injury.

**Gut-brain axis:** Jia et al. (2024 [Ref 32]) reported that theacrine-containing Kucha black tea modulated gut microbiota composition and increased brain 5-HT, DA, and BDNF while decreasing pro-inflammatory cytokines IL-6 and TNF-α in CUMS depression models.

**Bitter taste receptor activation:** Xie et al. (2024 [Ref 39]) identified that theacrine activates human bitter taste receptor hTAS2R14, with temperature-dependent binding affinity (stronger at 25°C than 45°C). *(Note: Ref 39 refers to PMID 39160053, included in the broad PubMed search but not separately retrieved — this data point is sourced from abstract text only.)*

**Biphasic dose-dependent profile:** The literature reveals an important dose-dependent duality. At low doses in rodents (3 mg/kg i.g.), theacrine acts as a sedative/hypnotic agent — increasing NREM sleep, shortening wake time, and augmenting pentobarbital-induced sleep via adenosine A₁/A₂A agonism-like activity (Qiao et al. 2017 [Ref 10]). At higher doses (24–48 mg/kg i.p.), theacrine induces locomotor activation via adenosine antagonism and dopaminergic mechanisms (Feduccia et al. 2012 [Ref 2]). This biphasic profile has not been formally characterized in humans.

### Pharmacokinetics

**Oral absorption:** Rapid. Wildgrube et al. (2025 [Ref 4]) found maximum salivary concentrations within 30 minutes of oral administration in 12 healthy volunteers. Strong correlation with caffeine absorption profile (Pearson r = 0.9865 in initial 40 minutes).

**Half-life:** Wildgrube et al. (2025 [Ref 4]) measured t½ = **21.00 ± 7.55 hours** in humans (salivary pharmacokinetics, ice capsule delivery). This is substantially longer than caffeine (~3–6 hours) but markedly shorter than the "5 days" figure in the seed data — see Gaps & Flags.

**Drug interaction with caffeine:** He et al. (2017 [Ref 3]) conducted a crossover PK study (n=8). Co-administration of caffeine (150 mg) with theacrine (125 mg) increased theacrine Cmax and AUC without altering theacrine's half-life. Theacrine had no impact on caffeine or paraxanthine pharmacokinetics. Enhanced oral bioavailability via presystemic mechanisms (efflux transport, gut metabolism) is the hypothesized mechanism. Hemodynamic parameters were unaffected.

**CYP enzyme involvement:** No direct metabolic pathway studies for theacrine have been published. By structural analogy with caffeine, CYP1A2 involvement is inferred and has been discussed in the literature (Tartar et al. 2021 [Ref 21] genotyped participants for CYP1A2*1F allele — allele status did not moderate outcomes, but this single study does not resolve the question). CYP1A2 involvement remains **structurally inferred, not experimentally confirmed** for theacrine specifically.

**Route of administration note:** All human pharmacokinetic and clinical studies in the published literature use **oral administration only**. See Gaps & Flags for a critical flag regarding the "insufflated" ROA in the brief's seed data.

---

## History

**First report (1937):** Theacrine was first reported as a minor component of *Camellia sinensis* leaves by Johnson in 1937 (pre-digital source, unverifiable via API). This represented the first characterization of the compound in the literature.

**Discovery in Kucha (1990s):** As part of research identifying novel Chinese tea resources, Ye and colleagues (1997, 1999) found that *Camellia assamica* var. *kucha* (Kucha), an unusual wild tea plant from southern China, accumulated large quantities of theacrine — the first discovery of theacrine as a major alkaloid in any plant. Endogenous levels of ~2.8% dry weight in young Kucha leaves were subsequently documented [Ref 16].

**Biosynthesis established (2002):** Zheng et al. (2002 [Ref 16]), published in *Phytochemistry*, established the first experimental demonstration that theacrine is biosynthesized from adenosine via caffeine. They mapped a three-step pathway: adenosine → xanthosine → theobromine → caffeine → 1,3,7-trimethyluric acid → theacrine, with S-adenosyl-L-methionine serving as the methyl donor. This remains the canonical biosynthesis reference.

**Molecular mechanisms of biosynthesis (2020–2026):** Zhang et al. (2020 [Ref 24]) identified theacrine synthase CkTcS in Kucha, showing N9-methyltransferase activity using 1,3,7-trimethyluric acid (not caffeine itself) as substrate, confirming C8 oxidation precedes N9 methylation. Zhu et al. (2025 [Ref 38]) cloned the caffeine oxidase gene CsCDH, establishing it as the rate-limiting enzyme. Wu et al. (2026 [Ref 37]) identified CsTcS2, a second theacrine synthase regulated by the CsTINY-CsWRKY33 transcription factor module.

**First pharmacological studies (2012):** Feduccia et al. (2012 [Ref 2]) published the first peer-reviewed pharmacological mechanism study, establishing adenosine and dopamine receptor involvement in theacrine's locomotor effects.

**Commercial market entry (2014):** Compound Solutions, Inc. announced an exclusive distribution license for TeaCrine® — a nature-identical, IP-protected form of theacrine — in June 2014 [Ref 30]. The first-in-human research was presented at the ISSN Conference in June 2014. A provisional U.S. patent application was filed November 2013. A U.S. patent (US10272091B2) covering theacrine-based supplement formulations was subsequently granted [Ref 31].

**Expanding research (2015–present):** A wave of human clinical trials followed commercial launch, primarily focused on cognitive enhancement, energy/mood, sports performance, and safety profiling. The compound remains commercially available as an unscheduled dietary supplement ingredient globally.

---

## Subjective Effects

The following is based on published controlled human studies only. No controlled human studies have characterized theacrine's psychoactive profile against a full effects taxonomy. User-reported effects not corroborated by controlled studies are noted where relevant.

**Energy and alertness:** Multiple RCTs report significant improvements in subjective energy ratings following oral theacrine. Ziegenfuss et al. (2017 [Ref 7]) found significant group × time interactions for energy, fatigue, and concentration with 200 mg. Kuhman et al. (2015 [Ref 6]) found higher subjective attentiveness, alertness, focus, and energy with a theacrine-caffeine combination vs placebo and caffeine alone, with reduced lethargy and grogginess. Taylor et al. (2016 [Ref 5]) found stable energy, focus, concentration, and motivation to exercise over 8 weeks without evidence of habituation.

**Focus and concentration:** Consistently reported as an effect in both acute and sub-chronic studies [Refs 5, 6, 7]. Combination with caffeine appears to enhance focus more than either agent alone [Ref 8, 28].

**Mood:** Ziegenfuss et al. (2017 [Ref 7]) found increased scores for willingness to exercise, motivation to train, and libido (at 200 mg over 7 days) with no increase in anxiety. Tartar et al. (2021 [Ref 21]) found caffeine alone increased self-reported anxiety whereas the caffeine + theacrine + methylliberine combination increased alertness without anxiety.

**Cognitive performance (objective):** Results are mixed. Kuhman et al. (2015 [Ref 6]) found no statistically significant improvement on TMT or DSST (cognitive tests). Stoke et al. (2026 [Ref 15]) found no significant cognitive performance effects at 3, 6, or 9 mg/kg. Gardiner et al. (2024 [Ref 14]) found no significant reaction time effects but found 400 mg reduced PVT lapses when consumed within 8 hours of bedtime. Lints et al. (2025 [Ref 28]) found caffeine+theacrine combination improved cognitive performance in military personnel under physical fatigue.

**Wakefulness/sleep:** Gardiner et al. (2024 [Ref 14]) found no significant effect of 100 mg or 400 mg theacrine on subsequent overnight sleep at any consumption timing (morning, afternoon, or evening), though the high dose showed small, non-significant effects on sleep efficiency. This contrasts with the low-dose sedative/hypnotic effect seen in rodents [Ref 10], possibly reflecting dose-dependent profile divergence across species.

**Duration (oral):** The brief states onset 30–60 minutes and total 6–10 hours for oral administration. Given the confirmed half-life of ~21 hours [Ref 4], peak subjective effects are likely longer-lasting than 6–10 hours in some individuals, though no human studies have systematically tracked subjective effects beyond 4–6 hours post-dose. The oral absorption data (Cmax within 30 min [Ref 4]) supports an onset of 30–60 minutes or faster.

**Effect profile assessment (based on literature):**
From the controlled study evidence, the following effects are reasonably supported:
- *Stimulation* — supported by multiple human studies [Refs 5, 6, 7, 8]
- *Wakefulness* — supported [Refs 5, 6, 7]
- *Focus enhancement* — supported [Refs 5, 6, 7, 21]
- *Motivation enhancement* — supported [Refs 5, 7]
- *Euphoria* — suggested by mood improvements; not formally characterized
- *Anxiety* — generally absent or reduced relative to caffeine at typical doses [Refs 21]; elevated cortisol at very high doses (9 mg/kg) [Ref 15]; may occur at higher doses
- *Appetite suppression* — inferred from stimulant class; no direct human data located
- *Music enhancement* — no published data; class inference only

---

## Safety & Toxicity

**Acute human safety:**
- Taylor et al. (2016 [Ref 5]) — 8-week RCT (n=60), 200 or 300 mg/day: all clinical safety markers (heart rate, blood pressure, lipid profiles, CBC, liver/kidney/immune biomarkers) remained within normal limits. No group × time interactions detected.
- Ziegenfuss et al. (2017 [Ref 7]) — no changes in resting heart rate, gas exchange, or hemodynamic parameters at 200 mg.
- Kuhman et al. (2015 [Ref 6]) — heart rate and blood pressure largely unaffected at combined theacrine + caffeine dose vs placebo.
- He et al. (2017 [Ref 3]) — no hemodynamic differences between theacrine alone, caffeine, and combination at PK study doses.
- Stoke et al. (2026 [Ref 15]) — no significant HR or BP effects at 3, 6, or 9 mg/kg, but elevated salivary cortisol at 120–180 min post-dose in theacrine conditions. The HPA axis response at very high doses warrants attention.

**Dose-dependent adverse effects (higher doses):**
Vieira-Cavalcante et al. (2025 [Ref 22]) — RCT (n=19 cyclists), 3 and 6 mg/kg theacrine: 6 mg/kg significantly elevated resting systolic and diastolic blood pressure. Reported side effects at both 3 and 6 mg/kg included: gastrointestinal discomfort, perception of tachycardia, dizziness, headache, head pressure, hand tremor, and lack of disposition. Authors concluded that the side effects may restrict its use as a supplement.

**LD50 / acute toxicity:** No human LD50 data published. No published animal LD50 data identified in the searched literature. The seed data notes "Acute: moderate; Chronic: moderate" toxicity — these appear to be class-inferred estimates. **Flagged as unverified against published sources.**

**Hepatotoxicity:** Li et al. (2013 [Ref 17]) demonstrated hepatoprotective rather than hepatotoxic effects in stressed mice (decreased ALT/AST, reduced inflammatory cytokines, reversed histological damage). Wang et al. (2018 [Ref 18]) found protection against NAFLD. No human liver toxicity data identified.

**Cortisol elevation:** Stoke et al. (2026 [Ref 15]) demonstrated increased salivary cortisol at high doses (3–9 mg/kg). Clinical significance at typical supplementation doses (200–400 mg) is unclear and would require further study.

**No case reports of overdose or serious adverse events** were identified in the searched literature.

**Contraindications:** No formally published contraindications for theacrine have been identified in the literature. By class analogy with caffeine and adenosine receptor antagonists: caution is warranted in individuals with anxiety disorders, cardiac arrhythmias, severe hypertension, or sensitivity to stimulants. Cardiovascular effects at high doses (≥6 mg/kg, equivalent to ≥420 mg for a 70 kg person) suggest particular caution for those with cardiovascular conditions. The cortisol-elevating effect at high doses suggests caution in HPA axis disorders.

---

## Harm Reduction

**Dosing guidance:**
- The 8-week safety study found 200–300 mg/day safe with no adverse clinical markers [Ref 5].
- Doses ≥6 mg/kg (~420 mg for 70 kg) have shown BP elevation and adverse side effects in some individuals [Ref 22].
- High doses (≥9 mg/kg, ~630 mg) elevate cortisol without improving cognitive performance [Ref 15].
- Separating theacrine consumption from bedtime by at least 4 hours appears sufficient to avoid sleep disruption [Ref 14].

**Caffeine interaction:** Co-administration with caffeine increases theacrine's plasma exposure (Cmax and AUC) [Ref 3]. This is pharmacokinetically significant. Users combining theacrine with caffeine-containing products may experience stronger effects than from theacrine alone.

**No recreational insufflation guidance available** — no published data exist on this route. See Gaps & Flags.

**Testing:** Theacrine may cross-react with caffeine on some immunoassay-based drug tests due to structural similarity, though this has not been formally studied. HPLC and MS-based methods are used for accurate identification in research settings.

---

## Tolerance & Dependence

**Tolerance:** Taylor et al. (2016 [Ref 5]) conducted an 8-week double-blind RCT (n=60) specifically examining habituation. Baseline values for energy, focus, concentration, anxiety, and motivation to exercise remained **stable across 8 weeks** in all groups (placebo, 200 mg, 300 mg). No tachyphylaxis or tolerance was detected — a finding explicitly described as distinguishing theacrine from caffeine and other neuroactive stimulants.

Feduccia et al. (2012 [Ref 2]) found no locomotor sensitization or tolerance in rats after chronic theacrine exposure, further supporting the non-habituating profile.

**Mechanisms:** The absence of tolerance is mechanistically attributed to theacrine's dual adenosine antagonism/dopamine facilitation profile, which may differ from caffeine in ways that prevent upregulation of adenosine receptors with chronic use. This hypothesis has not been directly tested with receptor binding studies.

**Dependence liability:** No published dependence liability assessments or withdrawal characterization studies were identified. The brief states "low" physical and psychological dependence with "low abuse potential" — consistent with the animal data (no sensitization) and the 8-week non-habituating profile in humans, but these are inferences. No formal abuse potential studies (e.g., self-administration paradigms) have been published.

**Half-life discrepancy (critical flag for tolerance data):** The brief states tolerance half-life of "5 days." The published pharmacokinetic data gives t½ = 21.00 ± 7.55 hours [Ref 4]. A 5-day (120-hour) half-life is not supported by any published source and would imply extreme accumulation with daily dosing. This figure should be corrected. See Gaps & Flags.

---

## Interactions

**Caffeine:** The most studied interaction. Caffeine (150 mg) co-administration increases theacrine Cmax and AUC without altering theacrine's half-life [Ref 3]. Likely mechanism: caffeine enhances theacrine's oral bioavailability via presystemic mechanisms. The combination does not appear to produce additive cardiovascular effects at typical doses [Ref 3, 6, 8]. The combination has been studied in several RCTs and shows cognitive/endurance synergy [Refs 8, 21, 28].

**Methylliberine (Dynamine®):** Mondal et al. (2022) found methylliberine co-administration decreased caffeine oral clearance and increased caffeine half-life, without a reciprocal effect on methylliberine. Theacrine + methylliberine showed no PK interaction. The three-way combination (caffeine + theacrine + methylliberine) has been studied in multiple esports/gaming RCTs [Refs 21] with apparent cognitive benefits and anxiety-sparing effects vs caffeine alone.

**CYP1A2 substrates:** By structural analogy with caffeine, theacrine is expected to be metabolized by CYP1A2. Tartar et al. (2021 [Ref 21]) genotyped participants for CYP1A2*1F allele — allele status did not moderate outcomes for the CDT combination, but this cannot be taken as a definitive finding about theacrine's CYP1A2 dependence.

**Stimulants:** Co-administration with other stimulants (amphetamines, MDMA, other xanthines) should be approached with caution due to additive adrenergic and dopaminergic burden. No published drug interaction studies exist for these combinations.

**Adenosine agonists:** Theacrine would be expected to antagonize exogenous adenosine agonists (e.g., regadenoson, adenosine infusion) — relevant in clinical/diagnostic settings.

**No published interaction data** exist for theacrine with: MAOIs, SSRIs, SNRIs, antihypertensives, antiarrhythmics, or CNS depressants. Interactions should be inferred from caffeine's profile until substance-specific data are available.

---

## Legal Status

**United States:** Theacrine is unscheduled at the federal level and is not a controlled substance under the Controlled Substances Act. It is commercially sold as a dietary supplement ingredient. TeaCrine® has U.S. patent protection [Ref 31] but the underlying compound is not scheduled. No FDA drug approval or NDI (New Dietary Ingredient) notification process publicly documented.

**WADA (World Anti-Doping Agency):** Theacrine does not appear on the 2025/2026 WADA Prohibited List. It is available as a sports supplement and is used by competitive athletes in multiple studies [Refs 8, 22, 23, 28]. No WADA prohibition was identified in searches. *(Note: formal GlobalDRO check was attempted but the database requires interactive search; status is based on absence of any prohibition in search results and marketing as a legal sport supplement.)*

**United Kingdom, European Union, Canada, Australia:** No scheduling or prohibition identified in searched literature or regulatory databases. Sold freely as a supplement ingredient in these markets. Compound Solutions' TeaCrine® is distributed globally. Exact classification under each jurisdiction's novel food/supplement frameworks (e.g., EU Novel Food Regulation) was not formally confirmed in this research.

**Analog act applicability:** Not applicable. Theacrine is a naturally occurring plant alkaloid with a distinct chemical structure from any scheduled substance.

---

## Clinical Trials

Three completed trials identified on ClinicalTrials.gov:

| NCT ID | Title | Status | Sponsor | Phase |
|---|---|---|---|---|
| **NCT07376564** | Assessing the Impact of High Theacrine Doses on Hemodynamic Measures, Cognitive Performance, and Physiological Stress | Completed | Titch Madzima | N/A |
| **NCT05170113** | Evaluate the Effectiveness and Safety of the Alpinia Galanga Formulation, Theacrine Formulation, and Caffeine Formulation on Fatigue, Mental Acuity, and Cognitive Health | Completed | Supplement Formulators, Inc. | N/A |
| **NCT06219161** | The Acute Effect of a Theacrine-based Supplement on Mobilization of Various Stem Cell Populations | Completed | University of Memphis | N/A |

Published results from NCT07376564 appear as Stoke et al. (2026 [Ref 15]). Results from NCT06219161 appear to correspond to Hellenbrand et al. (2024 [Ref 29]). No registered phase I–III drug trials were found; all trials are supplement/nutrition research.

---

## Community Feedback Analysis

No community feedback was submitted in Part A2 of the brief.

---

## Gaps & Flags

### ⚠️ CRITICAL FLAG — Half-life Error in Seed Data
**The brief's tolerance data states: "Half-life: 5 days."** Published pharmacokinetic data from Wildgrube et al. (2025 [Ref 4]) in 12 healthy human volunteers gives t½ = **21.00 ± 7.55 hours** (~21 hours). He et al. (2017 [Ref 3]) also reported on theacrine PK and found caffeine co-administration did not alter half-life, implying a consistent value below 24 hours. A 5-day (120-hour) half-life is not supported by any published source and is almost certainly a data entry error. **This value must be corrected in the database.** A full-tolerance reset of "1.5 weeks" (stated in the brief) is also inconsistent with a ~21-hour half-life; 4–5 half-lives would suggest near-complete clearance within ~4 days.

### ⚠️ CRITICAL FLAG — Insufflated ROA Not Supported by Published Evidence
**The brief states "primary ROA: insufflated" and "Known ROAs: oral, insufflated."** No published human or animal study, case report, pharmacological investigation, or user harm-reduction resource in any searched database documents theacrine insufflation. All human clinical studies and pharmacokinetic studies use oral administration exclusively. Theacrine is sold exclusively in oral forms (capsules, powders). The insufflated route has no published evidence and should be **removed or explicitly marked as unsourced speculation** in the database. Oral should be the primary documented ROA.

### ⚠️ SAFETY FLAG — Toxicity Ratings Not Source-Confirmed
**The brief states "Acute: moderate; Chronic: moderate" toxicity and explicitly notes "Inferred from pharmacological class — not sourced from literature."** No LD50 data for theacrine (human or animal) were identified in any searched database. The 8-week safety study (Taylor 2016 [Ref 5]) found no adverse clinical markers at 200–300 mg/day. Adverse effects emerge at ≥6 mg/kg (~420 mg for 70 kg) per Vieira-Cavalcante (2025 [Ref 22]). The toxicity characterization requires editorial review.

### ⚠️ DATA GAP — No Formal Binding Affinity Data (Ki/EC50)
No published Ki or EC50 values for theacrine at adenosine A₁, A₂A receptors or dopamine D₁, D₂ receptors were identified. Mechanism is established behaviorally and pharmacologically but formal receptor binding assay data are absent.

### ⚠️ DATA GAP — Metabolic Pathway and CYP Involvement Unconfirmed
CYP1A2 involvement is inferred from structural analogy with caffeine. No published metabolic pathway studies for theacrine exist. CYP1A2 polymorphism did not moderate CDT combination effects in one study [Ref 21], but this is insufficient to characterize the metabolic pathway.

### ⚠️ DATA GAP — No Published Human Stereochemistry Characterization
No stereochemistry issues were identified (theacrine is a symmetric structure with no stereocenters), but this has not been formally characterized in any published source.

### ⚠️ DATA GAP — Physical Properties (Melting Point, Aqueous Solubility, LogP)
No peer-reviewed published data on theacrine's melting point, aqueous solubility, or logP values were identified in the searched literature. PubChem's full data page was not retrievable during this session due to JavaScript requirements.

### ⚠️ DATA GAP — No Published Human PK Studies on Bioavailability
Absolute oral bioavailability has not been formally measured in humans. Wildgrube et al. (2025 [Ref 4]) provides salivary PK proxies. The mechanism by which caffeine enhances theacrine bioavailability (efflux transport vs gut metabolism) has not been confirmed [Ref 3].

### ⚠️ DATA GAP — Duration Data for Oral ROA
The brief states total duration of 6–10 hours (oral). Given the confirmed half-life of ~21 hours, subjective effects may persist longer than 10 hours for some individuals or at higher doses. No published study has tracked subjective effects beyond 3–6 hours post-dose. The 6–10 hour range is a reasonable estimate but should be noted as not directly validated in published controlled studies.

### ⚠️ FLAG — "Non-stimulatory" Descriptor in Biosynthesis Literature
Zhang et al. (2020 [Ref 24]) describe theacrine as "non-stimulatory" in the title of their biosynthesis paper. This characterization likely reflects the plant biology context (theacrine may not stimulate the plant's own adenosine receptors) and contrasts sharply with human pharmacological evidence showing stimulant effects at typical supplementation doses. The generation agent should not import this "non-stimulatory" label uncritically.

### ⚠️ DATA GAP — Legal Status in UK, EU, Canada, Australia
Formal regulatory status (e.g., EU Novel Food, TGA classification, Health Canada NPN status) was not confirmed with primary regulatory source documents. Theacrine is sold freely in these markets as a supplement ingredient, suggesting it is unscheduled, but precise classification was not verified.

### ⚠️ PROVENANCE FLAG — Johnson (1937) First Report
The first reported description of theacrine by Johnson (1937) is a pre-digital source referenced in secondary literature. It could not be directly retrieved or verified via available databases. Its date and authorship are cited in web-sourced summaries only.